Deal snapshot: Axsome Therapeutics Closes US Acquisition of Daytime Sleepiness Treatment Sunosi.

MANews-(C)2009-2022

US-based biopharmaceutical company Axsome Therapeutics, Inc. (NASDAQ: AXSM) has its US acquisition of Sunosi (solriamfetol) from Jazz Pharmaceuticals (NASDAQ: JAZZ), the company said.

Sunosi is a dual-acting dopamine and norepinephrine reuptake inhibitor indicated to improve wakefulness in adult patients with...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT